Highlight 4 in GU cancer
8 June 2023
Dr Frères reports in this video on the most exciting presentations during the oral abstract session on kidney and bladder cancer.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO – GU
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Post Congress Wrap-Up Meeting
On Tuesday 4th of July 2023, Prof. Dr Bertrand Tombal has moderated a panel discussion with esteemed Belgian experts, Prof Dr Christof Vulsteke and Dr. Emmanuel Seront. Together, they explored the practical applications of the latest research findings in GU Cancer.
This dynamic and interactive session provides valuable insights for healthcare professionals.
Daily highlights in GU
Highlight 3 in GU cancer
6 June 2023
Dr. Laure-Anne Teuwen shared her thoughts on some interesting abstracts presented during the poster discussion session on GU cancer, specifically kidney and bladder.
Highlight 2 in GU cancer
4 June 2023
During the presentation of the late-breaking abstract on the PEACE-1 study, Dr. Alberto Bossi, a radiation oncologist at Gustave Roussy in Villejuif, Paris, thoroughly discussed the study’s results.
Highlight 1 in GU cancer
3 June 2023
Prof Bertrand Tombal from Cliniques Universitaires St Luc in Brussels was asked by MediMix to choose noteworthy data from the poster discussion session on prostate cancer.
In-depth stories about GU
The CLEAR and CONTACT-03 study in renal cancer
12 June 2023
Dr Michael Serzan summarises the outcomes of the CLEAR and CONTACT studies in renal cell carcinoma and concludes with the impact of these data on current and future clinical practice.
Practice-changing THOR trial
11 June 2023
Dr Yohann Loriot, a medical oncologist at Institut Gustave Roussy in Villejuif, presented practice-changing data from the THOR trial. This study investigated the efficacy of the FGFR inhibitor erdafitinib in
Additional 3-month follow-up on cohort K of the EV-103 study
10 June 2023
Dr Terence Friedlander, a medical oncologist at the San Francisco Medical Center, shared insights on the current and future management of metastatic urothelial cancer. He discussed promising additional 3-month follow-up
Long-term outcomes of cohort A of the EV-103 study
9 June 2023
Dr Shilpa Gupta, a medical oncologist at the Cleveland Clinic, provided insights into the long-term outcomes of patients enrolled in the EV-103 study. This study evaluated the combination of enfortumab
Outcomes of the TALAPRO-2 study
8 June 2023
Dr. Karim Fizazi, medical oncologist at the Institut Gustave Roussy at Villejuif, discussed the outcomes of the TALAPRO-2 study, evaluating the combination of talazoparib and enzalutamide as first-line treatment for
5-year analysis of KEYNOTE-426
7 June 2023
Prof Brian Rini gives an overview of the current treatment landscape in renal cancer and extensively explains the 5-year analysis of KEYNOTE-426, evaluating pembrolizumab plus axitinib versus sunitinib as first-line
GU poster selection
Standard vs reduced dose of enzalutamide for frail elderly
6 June 2023
Dr Joanneke Overbeek, a pharmacist at Radboud University Medical Center in Nijmegen, the Netherlands, presented the outcomes of a multicenter trial comparing the standard dose of 160 mg once daily
The DUET study
6 June 2023
Prof. André Vis, a urologist at VUMC in Amsterdam, the Netherlands, presented the DUET study. This feasibility study evaluated the use of 177Lu-PSMA radioligand therapy alternated with radium-223 in patients
Final results from SAUL, a single-arm international real-world study of atezolizumab in advanced/metastatic urinary tract carcinoma
6 June 2023
Prof Dr Cora Sternberg shared her findings from the SAUL study. This study involved over 1000 patients with locally advanced or metastatic urothelial cancer who had failed previous treatment,